Results 251 to 260 of about 37,077 (282)
Some of the next articles are maybe not open access.
Bispecific Antibodies in Lymphoma
International Reviews of Immunology, 1993Journal Article ; Review ; SCOPUS: ar.j ; info:eu-repo/semantics ...
Brissinck, J +4 more
openaire +2 more sources
Production of Bispecific Antibodies
Current Protocols in Immunology, 1995AbstractBispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this ...
David M, Segal, Bert J E G, Bast
openaire +2 more sources
Immunotherapeutic perspective for bispecific antibodies
Immunology Today, 2000Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy.
A B, van Spriel +2 more
openaire +2 more sources
Diabodies: small bispecific antibody fragments
Cancer Immunology, Immunotherapy, 1997Although bispecific antibodies (bAb) are widely recognised to offer great promise in the therapy of malignancies and other diseases, significant difficulties in their production and purification have limited their progress to clinical application. Techniques employed to overcome this bottleneck in the production of clinical-grade bAb (starting from ...
P, Holliger, G, Winter
openaire +2 more sources
Bispecific antibodies rise again
Nature Reviews Drug Discovery, 2014Amgen's blinatumomab is setting the stage for a bispecific revival, enabled by new formats that may solve the field's long-standing problems.
openaire +2 more sources
Critical reviews in immunology, 1993
Bispecific antibodies--molecules combining two different antigenic specificities--are currently being developed as new agents for immunotherapy and for basic studies in cell biology. Bispecific antibodies (BsAb) are prepared by chemically linking two different monoclonal antibodies or by fusing two hybridoma cell lines to produce a hybrid-hybridoma ...
M W, Fanger, P M, Morganelli, P M, Guyre
openaire +1 more source
Bispecific antibodies--molecules combining two different antigenic specificities--are currently being developed as new agents for immunotherapy and for basic studies in cell biology. Bispecific antibodies (BsAb) are prepared by chemically linking two different monoclonal antibodies or by fusing two hybridoma cell lines to produce a hybrid-hybridoma ...
M W, Fanger, P M, Morganelli, P M, Guyre
openaire +1 more source
Catumaxomab: A bispecific trifunctional antibody
Drugs of Today, 2009The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells.
M, Sebastian +3 more
openaire +2 more sources
A revival of bispecific antibodies
Trends in Biotechnology, 2004Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the immune system effectively against pathogenic target cells. This complex task explains why, after more than 15 years of extensive research, many different formats of ...
Peter, Kufer +2 more
openaire +2 more sources
Chemical Production of Bispecific Antibodies
2004This chapter discusses two related methods for creating Fab' x Fab' chemically linked BsAb. Both methods require the generation of purified F(ab')2 fragments of each antibody and use reagents that react with the free thiols generated upon reduction of interheavy chain disulfide bonds of the F(ab')2 fragments. Upon reduction, the resulting Fabs are then
Robert F, Graziano, Paul, Guptill
openaire +2 more sources
Bispecific antibody therapy for lymphoma
Best Practice & Research Clinical HaematologyThe rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL.
Genevieve M, Gerhard +1 more
openaire +2 more sources